abt-510

ABT-510 is a synthetic peptide mimetic of thrombospondin-1 (TSP-1), developed by Abbott Laboratories as an antiangiogenic agent for cancer therapy. It functions by inhibiting angiogenesis both in vitro and in vivo, thereby slowing tumor growth. Mechanistically, ABT-510 blocks the actions of several proangiogenic growth factors critical to tumor neovascularization, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and interleukin 8 (IL-8). The drug induces apoptosis in endothelial cells and has demonstrated inhibition of tumor progression in preclinical models. It was investigated primarily for solid tumors, lymphoma, melanoma, and soft tissue sarcoma but did not demonstrate significant clinical efficacy as a single agent in phase II trials[1][4][5][6][8].

Other names

TSP-1 mimeticTSP1 mimeticTSP 1 mimeticthrombospondin-1 mimetic peptidethrombospondin1 mimetic peptidethrombospondin 1 mimetic peptide